Good results, but the market turns away
GSK’s third quarter had plenty of bright spots, but also exposed weaknesses:
- Core profit of 54.6 pence per share, beating the forecast of 50.4 pence.
- Revenue of £8.89 billion, above the forecast of £8.84 billion.
- Sales of specialty medicines for HIV, respiratory conditions and cancer jumped 15%.
- Revenue from vaccines and the newly launched asthma drug Exdensur missed expectations.
GSK maintained its full-year outlook, with revenue growth in the upper half of its 3%-5% range and core earnings per share growth in the lower half of its 7%-9% range. The company also said R&D spending is expected to grow faster than sales.
Investor concerns
According to analysts, much of the beat came from the timing of costs rather than underlying business momentum. Investors remain unsure where future growth will come from, with market forecasts for 2031 revenue of £36.64 billion well below GSK’s target of more than £40 billion.
Pipeline credibility is more of a medium-term concern.

















